Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on PK of Vepugratinib (LY3866288) in Healthy Participants
NCT06641037Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vepugratinib in urothelial carcinoma (UC) and solid tumor (2 cohorts), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration up to 3 weeks, Area Under the Concentration Versus Time Curve Extrapolated to Infinity up to 3 weeks and 1 more. Started Oct 2024; status: completed.
02
Drugs
vepugratinib
03
Conditions
urothelial carcinoma (UC)solid tumor
Beyond the preview
Go deeper on NCT06641037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06641037.